Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 9/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339975 | 1.00 | SCN10A (0.41) | SCN10AKCNH2SCN1ASCN5ASCN9A | |
| SCHEMBL30411878 | 0.82 | KDM4E (0.53) | NPY5RRIPK1 | |
| SCHEMBL24108255 | 0.82 | KDM4E (0.53) | NPY5RRIPK1 | |
| SCHEMBL22118349 | 0.81 | CYP1A1 (0.45) | NPY5RKIT | |
| SCHEMBL24108254 | 0.79 | DRD1 (0.41) | KIT | |
| SCHEMBL24107946 | 0.76 | SMN1; SMN2 (0.44) | NPY5R | |
| SCHEMBL30411254 | 0.76 | SMN1; SMN2 (0.44) | NPY5R | |
| SCHEMBL30340295 | 0.76 | KDM4E (0.49) | — | |
| SCHEMBL24107996 | 0.76 | KDM4E (0.49) | — | |
| SCHEMBL702063 | 0.73 | RAB9A (0.65) | SCN10AKCNH2SCN1ASCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281102-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4165022-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | Vertex Pharmaceuticals Incorporated (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20230011118-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| US-20230011118-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| WO-2021252859-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252859-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281102-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, NPC1L1 | SCN10A 2611/4885KCNH2 4043/4885SCN1A 2525/4885 |
| US-20230011118-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | SCN10A 2861/4885KCNH2 4357/4885SCN1A 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.